Advanced searches left 3/3

Peripheral Neuropathy - Springer Nature

Summarized by Plex Scholar
Last Updated: 15 July 2022

* If you want to update the article please login/register

Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer

This research sought to investigate the relationship between anxiety and depression before and the start of taxane-based chemotherapy and the rise of CIPN in breast cancer patients. After the last cycle of chemotherapy and 6 months after the end of therapy, patients completed questionnaires assessing anxiety and depressive signs before treatment and CIPN before therapy, 6 weeks after beginning of therapy, and 6 months after the end of therapy. During and after chemotherapy, the group of women with medium/high baseline anxieties showed a substantial rise in CIPN during and after chemotherapy than those with low baseline anxiety. Conclusion This research found that baseline medium to high anxiety and not depressive symptoms had an effect on CIPN formation during and after treatment, as shown by the 6 month study.

Source link: https://doi.org/10.1007/s00520-022-07093-4


The protective effect of chemical and natural compounds against vincristine-induced peripheral neuropathy (VIPN)

Vincristine, an alkaloid extracted from Catharanthus rosea, is a class of chemotherapy drugs that act by altering the microtubule function and inhibiting mitosis. Despite its widespread use, vincristine's greatest adverse effect of treatment is the occurrence of peripheral neuropathy, which limits treatment duration. Vitcristine-induced PN includes decreased calcium homeostasis, an increase of reactive oxygen species, increased tissue density, and the re-regulation of tumor necrosis factor-alpha and interleukin 1 beta expression. Several potential ways to deter the vincristine-induced PN have been proposed, including the concomitant administration of vincristine-containing chemicals.

Source link: https://doi.org/10.1007/s00210-022-02254-y


ECW/TBW is increased in type 1 diabetes mellitus patients with diabetic peripheral neuropathy: a retrospective case-control study

Purpose: To investigate the findings of body impedance testing in type 1 diabetes mellitus patients with diabetic peripheral neuropathy, see figure 1. Methods Used A total of 125 T1DM patients were chosen and enrolled into either the DPN group or the control group, according to the author's review. Conclusions The DNP group has elder age, longer diabetes occurrence, elevated blood urea nitrogen concentration, and a lower estimated glomerular filtration rate rate. The DNP group has a higher risk of other diabetic issues such as diabetic peripheral vascular disease and diabetic nephropathy. The DPN group had a higher percentage of extracellular water and total body water than the control group in BIA results, according to BIA results. In the ROC curve, the closest measure of ECW/TBW to diagnose DPN was 0. 3965, with the greatest cutoff of ECW/TBW to diagnose DPN at 0. 52 percent. Conclusion The increase of ECW/TBW may be a new risk factor for DPN, and it may help doctors predict the risk of DPN in T1DM patients.

Source link: https://doi.org/10.1007/s13410-022-01104-0


Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

oxaliplatin use in digestive tract cancers can result in severe peripheral neuropathy in patients and survivors, lowering the quality of life for patients and survivors. It will be the first clinical trial to establish the efficacy and safety of donepezil for OIPN management. According to a QLQ-CIPN20 sensory score, at least 6 months after the completion of an oxaliplatin-based chemotherapy will be included in adult cancer survivors with OIPN that display sensory neuropathy. Over 16 weeks of therapy, eighty patients will be randomly assigned to either donepezil or placebo. For a response rate of at least 30% in the donepezil arm, this model yields a type I error rate of 0. 0417 and power of 91%. Discussion of Dopezil's therapeutic interest in treating OIPN in the case of encouraging results This research will help launch a phase 3 controlled and placebo-controlled clinical trial to determine the therapeutic interest of the drug in treating OIPN.

Source link: https://doi.org/10.1186/s12885-022-09806-8


The effect of exercise therapy on balance in patients with diabetic peripheral neuropathy: a systematic review

Background Peripheral sensory and motor nerves are often affected in people with diabetes mellitus, and balance difficulties are widespread, as well as balance disorders. Diabetic peripheral neuropathy is common. This review looked at the effects of exercise therapy on balance parameters in diabetic peripheral neuropathy patients. These studies investigated the effects of exercise therapy on diabetic peripheral nerve pain patients with static, dynamic, and functional balance variables. Conclusions This research found that balance and intensification exercise improved static balance indices in diabetic peripheral neuropathy patients.

Source link: https://doi.org/10.1007/s40200-022-01077-1


Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy

Both the Neurofilament light chain and contactin-1 can be used as indicators of axonal and paranodal damage. We therefore hypothesized that serum NfL, CNTN1, C3b/c, and C4b/c may be biomarkers of disease activity in anti-MAG PNs. Methods We included 24 treatment-nau00efve patients with anti-MAG PN with IgM paraproteinemia, a high IgM MAG-antibody, and a clinical diagnosis of anti-MAG PN by a neurologist specialising in peripheral nerve disorders in this prospective cohort study. 10 treatment-nayence patients with IgM Monoclonal gammopathy of undetermined importance or Waldenstru00efve patients with a navance of neuropathy were included in the study, as controls, ten treatment-nau00efve patients with IgM Monoclonal gammopathy of undetermined importance or Waldenstru00efve patients with indivisible significance, with Macroglobulinemia without signs of neuropathy nau00efve gammopathy of una gammopathy of undefined gammopathy of undetermined na ef na nau00efe nau00efvu00efefhe na nau00efve gammopathy of undetermined nau00efau00efa nau00etru00efefefefve patients with undetermined au00efa Results in NfL, CNTN1 levels in serum were mostly healthy in anti-MAG PN patients and were similar to non-PN patients. C3b/c and C4b/c values were normal in anti-MAG PN patients, with C3b/c and C4b/c being similar.

Source link: https://doi.org/10.1007/s00415-022-10993-4


Is CT-based body composition associated with long-term chemotherapy-induced peripheral neuropathy in colorectal cancer survivors?

Background Chemotherapy-induced peripheral neuropathy is a common side effect among colorectal cancer survivors, and the severity is largely dependent on the chemotherapy dose. This study was intended to investigate the connection between body composition and long-term CIPN in CRC survivors 2–u201311 years after diagnosis. The abdominal CT scans were used to determine skeletal muscle mass, skeletal muscle mass, visceral adipose tissue, subcutaneous adipose tissue, and total adipose tissue. To investigate the connection between CIPN findings and body composition variables, logistic regression was used. More SAT was correlated with a higher likelihood of reporting total CIPN, motor CIPN, and sensory CIPN. No relationships of other body composition parameters with CIPN were found. We cannot say that based on these findings, determining the chemotherapy dose based on body composition is more effective than determining the chemotherapy dose based on body surface to avoid CIPN.

Source link: https://doi.org/10.1007/s00520-022-07036-z


Neuroprotective Effect of Baicalein Against Oxaliplatin-Induced Peripheral Neuropathy: Impact on Oxidative Stress, Neuro-inflammation and WNT/β-Catenin Signaling

Oxaliplatin, an effective anti-cancer agent used in the treatment of colorectal cancer, has been linked with severe dose-limiting side effects such as peripheral neuropathy, which is still a significant unmet medical need. Rats were given a dose of 4 mg/kg oxaliplatin i. p. Baicalein restored oxaliplatin-induced behavioral deficits in rats, and effectively avoided oxaliplatin-induced sensory nerve conduction deficits. Baicalein significantly improved the antioxidant defense system by raising the expression of MnSOD, HO-1, and GSH genes, according to a cellular review. The oxaliplatin-inflammation was reduced by the absence of inflammatory mediators like TNF-u03b1, IL-6, and a shunted NF-u03baB nuclear translocation, according to a reported decline in NF-u03b1. Baicalein treatment in Neuro2a cells attenuated oxaliplatin-induced ROS, mitochondrial superoxide levels, and improved neuritogenesis, in accordance with the in vivo results. In addition, baicalein did not alter the cell viability of oxaliplatin in the HCT-116 cell line.

Source link: https://doi.org/10.1007/s12035-022-02858-8


Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy

Background Cancer patients treated with neurotoxic chemotherapy are at risk of developing neurological disorders that can affect functional performance and quality of life. This report sought to reach agreement on reports concerning a CIPN assessment and management clinical pathway. Methods An expert multi-disciplinary panel and customers vetted a CIPN clinical pathway. 70 Australian respondents surveyed the agreement with 18 statements on four content themes, using a 2-stage Delphi poll process to reach consensus. Respondents graded reports using a 5-point Likert scale to determine the degree of agreement, with consensus agreed as u2265 80% of respondents supporting each claim. After stage 1 and all items after stage 2, the consensus was reached for 14 of the 18 items. The CIPN-path can assist teams across a variety of health care settings in detecting CIPN symptoms, aiding decision-making, and reducing morbidity from CIPN.

Source link: https://doi.org/10.1007/s00520-022-07024-3


Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized, Double-Blinded, Placebo-Controlled Trial

Objective To determine the effectiveness of Wen-Luo-Tong Granules local administration in the treatment of patients with peripheral neuropathy caused by chemotherapy or target therapy. Between July 2019 and January 2020, seventy-eight patients with PN related by chemotherapy or targeting therapy were admitted to China-Japan Friendship Hospital. The WLT group received WLT plus oral Mecobalamin for a week, while the control group received placebo plus oral Mecobalamin. After treatment, the PN grade in the WLT group was much lower than that in the control group despite being more active. The touch-detection thresholds at fingertips, neuropathy symptom score, QLQ-CIPN 20, and QLQ-C30 in the WLT group all improved after treatment compared to the control group. WLT's local administration was highly efficient in the care of patients with PN caused by chemotherapy or targeted therapy.

Source link: https://doi.org/10.1007/s11655-022-3575-y

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions